Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 595 entries
Sorted by: Best Match Show Resources per page
The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update.

European urology focus

El-Shater Bosaily A, Parker C, Brown LC, Gabe R, Hindley RG, Kaplan R, Emberton M, Ahmed HU.
PMID: 26839919
Eur Urol Focus. 2015 Sep;1(2):212-214. doi: 10.1016/j.euf.2015.04.007.

No abstract available.

Cite
El-Shater Bosaily A, Parker C, Brown LC, et al. The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. Eur Urol Focus. 2015;1(2):212-214doi: 10.1016/j.euf.2015.04.007.
El-Shater Bosaily, A., Parker, C., Brown, L. C., Gabe, R., Hindley, R. G., Kaplan, R., Emberton, M., Ahmed, H. U. (2015). The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. European urology focus, 1(2), 212-214. https://doi.org/10.1016/j.euf.2015.04.007
El-Shater Bosaily, Ahmed, et al. "The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update." European urology focus vol. 1,2 (2015): 212-214. doi: https://doi.org/10.1016/j.euf.2015.04.007
El-Shater Bosaily A, Parker C, Brown LC, Gabe R, Hindley RG, Kaplan R, Emberton M, Ahmed HU. The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. Eur Urol Focus. 2015 Sep;1(2):212-214. doi: 10.1016/j.euf.2015.04.007. PMID: 26839919; PMCID: PMC4694096.
Copy Download .nbib Format: NLM
The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted Robots.

European urology focus

Mottrie A, Larcher A, Patel V.
PMID: 30337191
Eur Urol Focus. 2018 Sep;4(5):629-631. doi: 10.1016/j.euf.2018.10.002. Epub 2018 Oct 15.

No abstract available.

Cite
Mottrie A, Larcher A, Patel V. The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted Robots. Eur Urol Focus. 2018;4(5):629-631doi: 10.1016/j.euf.2018.10.002.
Mottrie, A., Larcher, A., & Patel, V. (2018). The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted Robots. European urology focus, 4(5), 629-631. https://doi.org/10.1016/j.euf.2018.10.002
Mottrie, Alexandre, et al. "The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted Robots." European urology focus vol. 4,5 (2018): 629-631. doi: https://doi.org/10.1016/j.euf.2018.10.002
Mottrie A, Larcher A, Patel V. The Past, the Present, and the Future of Robotic Urology: Robot-assisted Surgery and Human-assisted Robots. Eur Urol Focus. 2018 Sep;4(5):629-631. doi: 10.1016/j.euf.2018.10.002. Epub 2018 Oct 15. PMID: 30337191.
Copy Download .nbib Format: NLM
Sperm Count and Hypogonadism as Markers of General Male Health.

European urology focus

Ferlin A, Garolla A, Ghezzi M, Selice R, Palego P, Caretta N, Di Mambro A, Valente U, De Rocco Ponce M, Dipresa S, Sartori L, Plebani M, Foresta C.
PMID: 31427194
Eur Urol Focus. 2021 Jan;7(1):205-213. doi: 10.1016/j.euf.2019.08.001. Epub 2019 Aug 17.

BACKGROUND: Some evidence suggests that infertile men, who are at increased risk for hypogonadism, metabolic derangements, and osteoporosis, have higher long-term morbidity and mortality than controls, but data are scarce and not conclusive.OBJECTIVE: We tested whether semen quality and...

Cite
Ferlin A, Garolla A, Ghezzi M, et al. Sperm Count and Hypogonadism as Markers of General Male Health. Eur Urol Focus. 2019;7(1):205-213doi: 10.1016/j.euf.2019.08.001.
Ferlin, A., Garolla, A., Ghezzi, M., Selice, R., Palego, P., Caretta, N., Di Mambro, A., Valente, U., De Rocco Ponce, M., Dipresa, S., Sartori, L., Plebani, M., & Foresta, C. (2021). Sperm Count and Hypogonadism as Markers of General Male Health. European urology focus, 7(1), 205-213. https://doi.org/10.1016/j.euf.2019.08.001
Ferlin, Alberto, et al. "Sperm Count and Hypogonadism as Markers of General Male Health." European urology focus vol. 7,1 (2021): 205-213. doi: https://doi.org/10.1016/j.euf.2019.08.001
Ferlin A, Garolla A, Ghezzi M, Selice R, Palego P, Caretta N, Di Mambro A, Valente U, De Rocco Ponce M, Dipresa S, Sartori L, Plebani M, Foresta C. Sperm Count and Hypogonadism as Markers of General Male Health. Eur Urol Focus. 2021 Jan;7(1):205-213. doi: 10.1016/j.euf.2019.08.001. Epub 2019 Aug 17. PMID: 31427194.
Copy Download .nbib Format: NLM
Tobacco Cessation: A Guide for Clinicians.

European urology focus

Brandt L, Fischer G.
PMID: 28723354
Eur Urol Focus. 2015 Aug;1(1):47-49. doi: 10.1016/j.euf.2014.10.004. Epub 2015 May 29.

Smoking behavior is a complex phenomenon that entails innumerable variables. Successful treatment interventions must be based on a comprehensive diagnosis and must consider the whole spectrum of factors influencing smoking behavior and nicotine dependence.

Cite
Brandt L, Fischer G. Tobacco Cessation: A Guide for Clinicians. Eur Urol Focus. 2015;1(1):47-49doi: 10.1016/j.euf.2014.10.004.
Brandt, L., & Fischer, G. (2015). Tobacco Cessation: A Guide for Clinicians. European urology focus, 1(1), 47-49. https://doi.org/10.1016/j.euf.2014.10.004
Brandt, Laura, and Fischer, Gabriele. "Tobacco Cessation: A Guide for Clinicians." European urology focus vol. 1,1 (2015): 47-49. doi: https://doi.org/10.1016/j.euf.2014.10.004
Brandt L, Fischer G. Tobacco Cessation: A Guide for Clinicians. Eur Urol Focus. 2015 Aug;1(1):47-49. doi: 10.1016/j.euf.2014.10.004. Epub 2015 May 29. PMID: 28723354.
Copy Download .nbib Format: NLM
Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.

European urology focus

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M.
PMID: 28723357
Eur Urol Focus. 2015 Aug;1(1):54-63. doi: 10.1016/j.euf.2015.02.001. Epub 2015 May 23.

BACKGROUND: Previous studies showed the prognostic impact of preoperative levels of neutrophil-to-lymphocyte ratio (NLR), plasma fibrinogen, and serum C-reactive protein (CRP) in surgically treated upper tract urothelial carcinoma; however, few papers have discussed the proper use of these indices.OBJECTIVE:...

Cite
Tanaka N, Kikuchi E, Kanao K, et al. Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis. Eur Urol Focus. 2015;1(1):54-63doi: 10.1016/j.euf.2015.02.001.
Tanaka, N., Kikuchi, E., Kanao, K., Matsumoto, K., Shirotake, S., Miyazaki, Y., Kobayashi, H., Kaneko, G., Hagiwara, M., Ide, H., Obata, J., Hoshino, K., Hayakawa, N., Kosaka, T., Hara, S., Nakagawa, K., Jinzaki, M., & Oya, M. (2015). Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis. European urology focus, 1(1), 54-63. https://doi.org/10.1016/j.euf.2015.02.001
Tanaka, Nobuyuki, et al. "Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis." European urology focus vol. 1,1 (2015): 54-63. doi: https://doi.org/10.1016/j.euf.2015.02.001
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M. Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis. Eur Urol Focus. 2015 Aug;1(1):54-63. doi: 10.1016/j.euf.2015.02.001. Epub 2015 May 23. PMID: 28723357.
Copy Download .nbib Format: NLM
Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking.

European urology focus

Briganti A, Giannarini G.
PMID: 28723363
Eur Urol Focus. 2015 Aug;1(1):90-91. doi: 10.1016/j.euf.2015.07.002. Epub 2015 Aug 01.

No abstract available.

Cite
Briganti A, Giannarini G. Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking. Eur Urol Focus. 2015;1(1):90-91doi: 10.1016/j.euf.2015.07.002.
Briganti, A., & Giannarini, G. (2015). Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking. European urology focus, 1(1), 90-91. https://doi.org/10.1016/j.euf.2015.07.002
Briganti, Alberto, and Giannarini, Gianluca. "Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking." European urology focus vol. 1,1 (2015): 90-91. doi: https://doi.org/10.1016/j.euf.2015.07.002
Briganti A, Giannarini G. Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking. Eur Urol Focus. 2015 Aug;1(1):90-91. doi: 10.1016/j.euf.2015.07.002. Epub 2015 Aug 01. PMID: 28723363.
Copy Download .nbib Format: NLM
Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Primary Chemotherapy.

European urology focus

De Santis M.
PMID: 28723364
Eur Urol Focus. 2015 Aug;1(1):91. doi: 10.1016/j.euf.2014.12.003. Epub 2015 May 26.

No abstract available.

Cite
De Santis M. Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Primary Chemotherapy. Eur Urol Focus. 2015;1(1):91doi: 10.1016/j.euf.2014.12.003.
De Santis, M. (2015). Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Primary Chemotherapy. European urology focus, 1(1), 91. https://doi.org/10.1016/j.euf.2014.12.003
De Santis, Maria. "Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Primary Chemotherapy." European urology focus vol. 1,1 (2015): 91. doi: https://doi.org/10.1016/j.euf.2014.12.003
De Santis M. Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Primary Chemotherapy. Eur Urol Focus. 2015 Aug;1(1):91. doi: 10.1016/j.euf.2014.12.003. Epub 2015 May 26. PMID: 28723364.
Copy Download .nbib Format: NLM
The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer.

European urology focus

Lerner SP, Weinstein J, Kwiatkowski D, Kim J, Robertson G, Hoadley KA, Akbani R, Creighton C.
PMID: 28723366
Eur Urol Focus. 2015 Aug;1(1):94-95. doi: 10.1016/j.euf.2014.11.002. Epub 2015 Jun 06.

The Cancer Genome Atlas project in bladder cancer reported the integrated genomic analysis of the first 131 patients in 2014. This muscle-invasive cohort was found to have one of the highest somatic mutation rates. The analysis working group will...

Cite
Lerner SP, Weinstein J, Kwiatkowski D, et al. The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. Eur Urol Focus. 2015;1(1):94-95doi: 10.1016/j.euf.2014.11.002.
Lerner, S. P., Weinstein, J., Kwiatkowski, D., Kim, J., Robertson, G., Hoadley, K. A., Akbani, R., Creighton, C. (2015). The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. European urology focus, 1(1), 94-95. https://doi.org/10.1016/j.euf.2014.11.002
Lerner, Seth P, et al. "The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer." European urology focus vol. 1,1 (2015): 94-95. doi: https://doi.org/10.1016/j.euf.2014.11.002
Lerner SP, Weinstein J, Kwiatkowski D, Kim J, Robertson G, Hoadley KA, Akbani R, Creighton C. The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. Eur Urol Focus. 2015 Aug;1(1):94-95. doi: 10.1016/j.euf.2014.11.002. Epub 2015 Jun 06. PMID: 28723366.
Copy Download .nbib Format: NLM
Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials.

European urology focus

Martins-Silva C, Cruz F.
PMID: 28723381
Eur Urol Focus. 2016 Aug;2(3):329-331. doi: 10.1016/j.euf.2016.04.003. Epub 2016 Apr 26.

Bladder injections of 200U onabotulinumtoxinA have similar efficacy in the treatment of urinary incontinence in patients with multiple sclerosis or spinal cord injury. The effect is maintained in the long term without significant adverse events.

Cite
Martins-Silva C, Cruz F. Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. Eur Urol Focus. 2016;2(3):329-331doi: 10.1016/j.euf.2016.04.003.
Martins-Silva, C., & Cruz, F. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. European urology focus, 2(3), 329-331. https://doi.org/10.1016/j.euf.2016.04.003
Martins-Silva, Carlos, and Cruz, Francisco. "Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials." European urology focus vol. 2,3 (2016): 329-331. doi: https://doi.org/10.1016/j.euf.2016.04.003
Martins-Silva C, Cruz F. Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. Eur Urol Focus. 2016 Aug;2(3):329-331. doi: 10.1016/j.euf.2016.04.003. Epub 2016 Apr 26. PMID: 28723381.
Copy Download .nbib Format: NLM
Clinical Case Discussion: Repeat Sling Surgery-Should We Offer a Second Sling?.

European urology focus

Vandercruysse F, De Ridder D, Van der Aa F.
PMID: 28723383
Eur Urol Focus. 2016 Aug;2(3):334-335. doi: 10.1016/j.euf.2016.06.019. Epub 2016 Jul 12.

Advantages of secondary sling surgery for persistent or recurrent stress urinary incontinence include low complexity and short operation time, low blood loss, and short hospitalization. Rates of perioperative complications, erosion, and postoperative voiding difficulties are comparable with primary sling...

Cite
Vandercruysse F, De Ridder D, Van der Aa F. Clinical Case Discussion: Repeat Sling Surgery-Should We Offer a Second Sling?. Eur Urol Focus. 2016;2(3):334-335doi: 10.1016/j.euf.2016.06.019.
Vandercruysse, F., De Ridder, D., & Van der Aa, F. (2016). Clinical Case Discussion: Repeat Sling Surgery-Should We Offer a Second Sling?. European urology focus, 2(3), 334-335. https://doi.org/10.1016/j.euf.2016.06.019
Vandercruysse, Femke, et al. "Clinical Case Discussion: Repeat Sling Surgery-Should We Offer a Second Sling?." European urology focus vol. 2,3 (2016): 334-335. doi: https://doi.org/10.1016/j.euf.2016.06.019
Vandercruysse F, De Ridder D, Van der Aa F. Clinical Case Discussion: Repeat Sling Surgery-Should We Offer a Second Sling?. Eur Urol Focus. 2016 Aug;2(3):334-335. doi: 10.1016/j.euf.2016.06.019. Epub 2016 Jul 12. PMID: 28723383.
Copy Download .nbib Format: NLM
Grey Zone: Urinary Incontinence.

European urology focus

Tubaro A, Nambiar AK.
PMID: 28723385
Eur Urol Focus. 2016 Aug;2(3):337-338. doi: 10.1016/j.euf.2016.03.009. Epub 2016 Apr 16.

Providing high-quality evidence in the field of urinary incontinence is difficult because the value of diagnostic tests must be evaluated through the filter of treatment outcome, and surgical treatments include an unavoidable amount of intrinsic variability. The scientific community...

Cite
Tubaro A, Nambiar AK. Grey Zone: Urinary Incontinence. Eur Urol Focus. 2016;2(3):337-338doi: 10.1016/j.euf.2016.03.009.
Tubaro, A., Nambiar, A. K. (2016). Grey Zone: Urinary Incontinence. European urology focus, 2(3), 337-338. https://doi.org/10.1016/j.euf.2016.03.009
Tubaro, Andrea, et al. "Grey Zone: Urinary Incontinence." European urology focus vol. 2,3 (2016): 337-338. doi: https://doi.org/10.1016/j.euf.2016.03.009
Tubaro A, Nambiar AK. Grey Zone: Urinary Incontinence. Eur Urol Focus. 2016 Aug;2(3):337-338. doi: 10.1016/j.euf.2016.03.009. Epub 2016 Apr 16. PMID: 28723385.
Copy Download .nbib Format: NLM
Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up.

European urology focus

Dagher J, Kammerer-Jacquet SF, Brunot A, Pladys A, Patard JJ, Bensalah K, Perrin C, Verhoest G, Mosser J, Lespagnol A, Vigneau C, Dugay F, Belaud-Rotureau MA, Rioux-Leclercq N.
PMID: 28723401
Eur Urol Focus. 2016 Feb;1(3):284-290. doi: 10.1016/j.euf.2015.06.001. Epub 2015 Jun 17.

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with 50% risk of metastases at initial diagnosis or at follow-up. An inactivation of the tumor-suppressor gene von Hippel-Lindau (VHL) is present in >70% of sporadic cases by...

Cite
Dagher J, Kammerer-Jacquet SF, Brunot A, et al. Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up. Eur Urol Focus. 2015;1(3):284-290doi: 10.1016/j.euf.2015.06.001.
Dagher, J., Kammerer-Jacquet, S. F., Brunot, A., Pladys, A., Patard, J. J., Bensalah, K., Perrin, C., Verhoest, G., Mosser, J., Lespagnol, A., Vigneau, C., Dugay, F., Belaud-Rotureau, M. A., & Rioux-Leclercq, N. (2016). Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up. European urology focus, 1(3), 284-290. https://doi.org/10.1016/j.euf.2015.06.001
Dagher, Julien, et al. "Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up." European urology focus vol. 1,3 (2016): 284-290. doi: https://doi.org/10.1016/j.euf.2015.06.001
Dagher J, Kammerer-Jacquet SF, Brunot A, Pladys A, Patard JJ, Bensalah K, Perrin C, Verhoest G, Mosser J, Lespagnol A, Vigneau C, Dugay F, Belaud-Rotureau MA, Rioux-Leclercq N. Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up. Eur Urol Focus. 2016 Feb;1(3):284-290. doi: 10.1016/j.euf.2015.06.001. Epub 2015 Jun 17. PMID: 28723401.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 595 entries